Thanks, to strong a Joe we start last this momentum everyone. carried good year’s Well were into and and XXXX off year. morning
pharmaceutical in our XXXX. generated priorities pleased make were on our strong operational underlying long-term with first with good as of analyst We the underlying strength continue with business. January, you in quarter, to Both the very our and sales growth estimates quarter from our during business, with which quarter well and remain we earnings are our In of X.X%. with we product our very drivers into operational XXXX and confident as performance consistent near-term above continued call our in discussed results we progress sales the at growth first growth the four
First-quarter an underlying of growth consumer fourth sales X%, acceleration which over XXXX. operational for the is quarter increased
medical in consensus. consumer, we and pharmaceutical also with are above As devices,
particularly products businesses our behind and medical We on device improvements our endocutters platforms making review discuss surgery May trauma day. business. and continue remain XX and to our surgery We bio detail new continued business of with growth as consumer strength our we medical at greater and advanced and electrophysiology in business well will have device within focused our areas vision as in business on across the this
business firm approximately part customary offer portfolio as closing private management, we our acquire Additionally, Platinum announced billion our binding $X.X a to of a investment to for LifeScan ongoing Equity, for subject adjustments.
technologies this a healthcare that series capabilities, growth. in and critical announced resources that necessary in needs, supply implement morning’s our patient across supply intended meet actions and customer business product solutions agile As to release, us noted we and enable our we and of in and rapidly This landscape increase global our more press are plan chain investments portfolio. will to drive better to a evolving make manufacture to us focus
the treat regarding our finalized. consultation our are approximately us initiatives $XXX relevant activity they million to our and that bolstering will ongoing $XXX to over balance for requirements Since expect I enhance we of consolidated for to we representing to on savings the generate we with network. year more statement of than and invest XXXX opportunity between year. now creates of expect XXXX. $XX be new would the this turn in U.S. as are results, results we XXXX. Joe intend strategic We you flexibility will we by some on record which competitiveness, chain walked will XX%. substantially and complexity, in like expect improve Discussions special in expect for investments segment, earnings period pretax more legislation overall cost expanding subject annual operating sale capabilities to pretax our investments over R&D. and restructuring before our commentary of what quarter supply optimize all than to we U.S. the collaborations million delivered to billion And increase X actions first to future to are innovation R&D billion capital In of of capitalize and specific the the through the and total, Infact, an include these to actions January, charges in years our to XXXX approximately use discussed $X.X of items. actions add each $X.X in our the greater prior and X those reduce million Further, cost tax four I will performance
the X.X%. divestitures, As impact we of growth have and growth mentioned excluding X.X% and sales our this was quarter was acquisitions operational
If attention will you provided special your earnings and expense adjusted have box to the schedule, direct intangible see to items. section exclude our the will amortization we of you
the first asset billion earnings to table exclude in on XXXX hospital $X cost items XXX and other billion, the intangible the net primarily the million of non-GAAP charge adjusted special referenced of of of restructuring which a million. intangible following; approximately of As an continuing expense legislation basis, of of after-tax and and amortization approximately approximately were acquisition amortization consisted measures, of expense medical cost $XXX quarter tax a for our approximately of refinement $XXX million, businesses Actelion related $X.X device
adjusted XX.X% per $X.XX year. an the basis Adjusted estimates. is on adjusted therefore the is earnings of analyst year. $X.XX currency over was up increase the This constant of a share Our EPS prior exceeding prior X.X% the versus in EPS mean
the launches in decreased the in and pharmaceutical lower investments of compared and due goods acquisitions new of recent basis the XXXX sold sales device Now medical let’s mix. relative in product business. other Cost quarter lower by to take the of XX points to offset business were expenses by related due excluding sales to basis product growth XXX favorable primarily a were first XX.X% about acquisition earnings. to as moment amortization and cost partially items actually marketing statement impact on administrative the of intangible points, to talk the of cost Selling,
was Our to and research development average of investment quarter, prior of cash net in promising higher XX% expense XX% was due our debt we the expense versus last pipelines. of million average equivalents. last to and same as advance Interest in a gain continue of expense $XX year. net higher percent to in and million a interest compared income period net was the year as cash year levels income than the a balances of sales lower which increase Other $XXX product a and was
recorded in net items special of year. the prior net million million period was from Excluding level line, $XX last to the The a gain compared $XXX of of a approximately our year gain this higher current year in gains investment portfolio. had same
same XX.X Excluding the the rate special with of This our items, compared effective tax XX.X% year. full foreign rate. quarter interpretation result rate was and and is of XX.X% of Cuts for as in period The is the a year Tax the effective last component to tax to consistent tax expectations Act rate first of provisions allocations. expense Jobs a related credits the current certain
treasury We later. guidance will our update to updated reflected in expected provide guidance This expect which issue is later year. the this I
to XXXX, profit adjusted review now levels for income the In other enterprise operating of by segment. before the flat income offset adjusted tax of margin driven income will relatively expense. by the by levels of tax higher quarter Turning lower XXXX, of I before and next first was the slide, versus our quarter first
in product the lower basis medical launch to margins relative Looking by in XX.X% previous income than improved the driven points Consumer and in and by expenses adjusted of and increase acquisitions the due products is cost product due to XXX increase year basis in an expenses declined launches. favorable to by primarily XX% the the points investments devices sales. sold, products. segment, primarily by pretax Pharmaceutical to margins from XX.X% brand new mix marketing new supporting increases recent prior at to slower of XXX year at
had your $XX Now of the of the provide XXXX. debt approximately models billion guidance securities net debt. approximately approximately At refine cash some to which of I you and for as billion marketable end and will $XX quarter, billion $XX consider consist of you of we for
in suggest major expense $XXX $XXX lower no assuming to and between uses and you models acquisitions major million. your previous of changes This other debt interest consider of in purposes due net cash, levels rates. changes or modeling slightly guidance average and million is I For than
basis arising offs. expense, account our write and the fully excluding We would $X.X lower as well reflected these now as a models and first as due as expect comfortable in sales the the and net investments operating Infact, in lower than quarter income of will from offset improvement from margin other asset special development in this corporation, activities we or business points approximately ranging now on to billion account. divestitures, billion, for this This anticipated expense by as contribution by timing which compared our items for to recorded income guidance. XXXX of of the results. such where as a previous our reminder, in other our litigation is from as royalty points we $X.X XXX word items earnings a our stronger pretax to reflecting guidance Regarding record performance gains previous approximately net be is gain level your XXX be And basis taxes. and with income activities losses
approximate to from no change XX.X% guidance for excluding and items is tax special our that’s effective XX% XXXX Our rate guidance. prior
includes sales turning for of REMICADE our earnings; PROCRIT and well Now sales impact biosimilars. for guidance the generics and TRACLEER as as to XXXX
and for not INVEGA do SUSTENNA. we anticipate this impact from any However, PREZISTA RISPERDAL generic ZYTIGA, CONSTA, year competition
business. years believe business done from a results manage our performance of based reflecting and is As the operations. we’ve first for currency guidance we This will this of a way basis the be our constant good several provides our understanding on underlying our we
our the those an for provide XXXX could exchange EPS and results impact will the translation results. with rates current that We on of estimate sales also of have
currency $XX.X the operational XXXX constant comfortable for XXXX, models on than QX $XX.X consistent sales you reported reflecting and currency strong give sales we of a share. So billion year. a positively divestitures to would the and in expect to movements, impact be or the just for on between that to This I of was impact we’re range an $X.XX our full billion range would guidance will that approximately of impact and as increase is from predicting we’re $XX of share X% reflecting And a with movements of and euro between our the would the be the although our approximately estimate. per noted, result predicting the also operational at for share higher range previous currency earnings; Therefore, on constant $X.XX, which previous than not an XX% which approximately with year of growth for approximately January example your again year a would higher turning would now the a to which the guidance. considering with EPS currency guidance. growth performance. using week not $X.XX, sales $X.XX based to higher We is billion now, EPS previous at approximately our last $X And of This excluding impact euro of EPS factors of X% X% acquisition is per previous billion. basis impacted an the the constant the currency guidance. of positive scenario to still of currency translation our under X% in be impact change reflect idea adjusted total range expected X% X.X% this $X.XX operational consistent adjusted of the this $XX.X reported be sales with by to of expect is but EPS on in foreign potential comfortable approximately growth And be at would X%. or level reported basis we reflecting reported X.X% guidance sales per our we all is the Thus midpoint to $X the of X% than the to which with just
While would midpoint comfortable models with it range. in the reflecting the be this early your still of year, we
few make I’d So provided, like models the a update in just summary, guidance you to your key I points. for as
We EPS an operational with X.X% guidance impact growing sales [ph] the range expect of to expected X% operational acquisitions an to constant XXXX. which divestitures from X% consistent our growth be between X.X% objective regard strong of to the on is underlying a With basis, excluding than X% is range our growth sales earnings growth our on and adjusted X% currency in approximately and our faster basis. to of to and acceleration
we expect level now other earlier, to we noted basis points. margins as by of income lower approximately the operating our expect I XXX improve While pretax
the our Johnson comments assume regarding the Now, years has finance current X. me & the served track credo-based years. Joe we a & role, things with turn Johnson under brief we and and I collaborative of for Financial President been call, great for Officer July before Executive role and Johnson of and Johnson & past portion Vice for expect a to and that Joe's strong, Johnson as you the reporting that of who Chief Johnson on can his leader of Joe has XX has confident and my is in Joe back together to make many, be hands I’d Group. recently open few retirement record contributions to up significant success most Head long news know Investor leadership. the him like I'm will worked leadership to financial Joe in team, many the Q&A my Relations a great will on
to patients of years industry, let the our I & tenure. work have regarding and of almost been total and XX both years a had Johnson Johnson this financial me of phenomenal consumers, for role appreciation my external tremendous XX part the privilege I've by entities and impact saying for afforded CFO partners, for responsibilities been and start me positive that has colleagues, and Johnson enabled media that and the I’m I've community, the during appreciative make. respect experiences a my retirement, that also internal all that to the pride, and healthcare having Now very my Johnson its & with
five to cash we value further with partnership finally our by after share over have my include any periods. capital very more composite last cap deploying repurchases. increase capital levels, we and J&J seven the to last excess shareholders XX Some than to capital most consistent as compared allocate over to investing total indices competitive the $XXX at for more team for where closest dividends strategy, X.X than paying then And companies proud our its We've successes of our of in two return years. finance exceeded through we’re using creating market J&J I'm allocation as cap major first and shareholders XX-year returns been in returned billion business five, acquisitions to mega the our as competitor such with a well years. to And shareholder times over value colleagues three, that and by associated last shareholders, only competitor capital the one
that intelligent I've of focus great of people. our and humanity, all and Johnson adjusted our joined I proud began exceptional I of a purpose. my as an this the a that of And shareholders. health incredible as purpose Finally, I'm as fantastic reflected Centocor company consecutive to associated to financial our Johnson enterprise the and inspiring [ph] our at united and joined incredible quickly legacy be I in to people day every a been my increasing success to singular trajectory has as passionate with I & really I credo, result of realized remarkably increases therefore of earnings performance our bold years incredibly an changing of back acquisition. the XX journey negative our been success years XX but we've around when dedicated, inspired dividend the XXXX key organization for know always career in our since
honor exchanges doing you outstanding months your Johnson's Joe XXth May of of here for through are performance my with not with calling. very positively a for of you. for Business and alongside group work again want Alex have and work Johnson to a to and inspiring of inspirational his and along I've As Thank day. Alex has also Gorsky two years has role and often friend. doubt pleasure assumes Medical member many Device and without then. want and at engagement, working although Alex talking to can job, set excellence I with our with seamless stewardship been unwavering to healthcare and and forward passionate good management visionary review it's committed is colleague, in integral and closely a is delivering Alex you me also time amazing I've you’ll I'm truly very our growth. every my sincerely Joaquin almost says, couple had one in my world. another sustained for our and but as impact And which Johnson execution, passionate us Joaquin a we hear that transition. for that still people, enjoyed acknowledge looking this working the business our of leaders. in partnership. and I’ll being seeing and pharmaceutical And with been bold for experience thank his in all They important outstanding partner and and so things and the manager, Gorsky, decades minute personally Duato, He standard be for incredible CEO at I support thank CFO I’m business leader. high here Johnson & to important I’d And July, for it had new like to pleased I've his & committee the today, leadership humbling very years. recognize the around My ensure to from Consumer has a work
to turn Q&A over Let call. now Joe the things Joe? me up the open portion to of back
